Sequential Stabilization on the Menu; Margin Recovery Will Set the Tone
After Q1's PAT surge but 30% revenue drop, the Street watches for stabilization on capacity utilization and the margin trajectory ahead of ₹2,200 Cr full-year targets.
The Setup: When Sequential Matters More Than YoY
ELECON trades at ₹441.25, well below the Street's median ₹600 target—a 35% gap that reflects skepticism about near-term execution despite full-year growth expectations of 15.7% CAGR. Q1 FY27 (₹521 Cr, up 6% YoY but down 30% from Q4's ₹745 Cr) spooked sequentialists. The real question: Is that Q4 spike a seasonal peak or does Q2 prove the new normal is a plateau, with upside coming only Q3 onwards as capacity expansions unlock? The margin story is just as critical—Q1 PAT surged 1,072% YoY (to ₹70.35 Cr) on lower cost base, but did that rebound hold? Consensus assumes it did. The Street is pricing a modest sequential recovery and margin stabilization at 13–15% PAT range.
~₹550–580 Cr
Stabilization post-Q1; YoY base Q2 FY26 ₹578 Cr (likely flat to +3% YoY if demand holds)
13–15%
Q1 printed ~13.5% (₹70.35 Cr on ₹521 Cr revenue); recovery embedded in full-year ₹2,200 Cr guide
Q2–Q3 ramp
New foundries + Mexico Grupo Radicon (incorporated June 2026) capacity payoff; capex burden eases if utilization >70%
Supports FY27 growth
Not quantified in latest filings; management commentary on call will be the tell on pricing power and mix
A strong print would show: (a) Revenue hold/modest uptick from Q1 (₹535+ Cr)—proving Q4's seasonal weakness, not a cliff. (b) PAT margin stable or expanding into 14%+ territory—capex efficiencies kicking in, or higher-margin export orders flowing. (c) Management guidance reaffirming or tightening the ₹2,200 Cr full-year, with Q3/Q4 visibility lifting. A weak print would trigger: (a) Revenue stalling below Q1 (₹500 Cr)—demand deflation or order delays. (b) PAT margin contracting to <12%—cost inflation or lower-margin mix (domestic vs export). (c) Capex or working-capital headwinds delaying the Q2/Q3 utilization ramp.
On Track with Full-Year Targets?
ELECON has guided for ~₹2,200 Cr full-year FY27 revenue (implicit from April–Oct media). Year-to-date through Q1: ₹521 Cr. That leaves ₹1,679 Cr for three quarters, averaging ~₹560 Cr/quarter. Q2 at ₹550–580 Cr keeps the glide path intact. The margin inflection from capex benefits is also embedded—if Q1's 13.5% PAT margin is the trough and Q2–Q4 see 14–15%, the ₹2,200 Cr guide at ~14% margin implies ~₹300+ Cr PAT for the year (vs ~₹260 Cr prior-year run-rate). This is accretive and in line with post-capex efficiency expectations. No surprises in the trajectory so far; result day will confirm whether momentum shifts or stalls.
The Street: Full Conviction
Since Last Quarter: What Changed
1 · Board Meeting & Results Date
Oct 14, 2026: Board to approve Q2 unaudited results (standalone & consolidated) and declare dividend. Trading window closed Oct 1; will reopen 48 hours post-result. Routine governance, but watch the dividend action as a signal of confidence on cash generation.
2 · Capacity Expansion: Mexico Subsidiary Completion
Grupo Radicon SA de CV (step-down subsidiary) incorporated in Mexico June 2026. This is ELECON's play to tap Latin American capex demand and diversify away from India+Europe concentration. No revenue impact expected until H2 FY27/FY28, but it signals management confidence in pipeline. Watch for commentary on Mexico ramp costs and order pipeline.
3 · Ownership & Pledges
FII 6.99% (down from 9.62% a year ago, -260 bps), DII 7.18% (up from 3.78%, +340 bps), promoter steady at 59.27%. FII selling into strength (price near 52w high of ₹579 in H1, now -24% from peak) suggests patience on capex payoff among foreign accounts. No pledges noted in recent filings—balance sheet remains clean.
4 · Board Appointment
Pranav C. Amin appointed Additional Director (Non-Executive, Independent) June 22, 2026. Governance refresh; routine. No operational red flags.
What to Watch on Result Day
1 · Sequential Revenue & Margin Print
₹550–580 Cr revenue stabilization is the bar; below ₹535 Cr breaches confidence. PAT margin above 14% (on base ~13–13.5%) suggests capex efficiency and mix strength. Below 12% is warning. Management's Q2–Q4 volume/utilization commentary will trump the number itself.
2 · FY27 Guidance Reaffirmation & Commentary
Is ₹2,200 Cr FY27 on track? Any update on Q3/Q4 pipeline, export order pace, or pricing environment? Mexico capex burn and timeline to first revenue? A tightened or raised guide lifts confidence; a lowered guide or vague commentary invites selling.
3 · Capex Spend & Working Capital Headwind
How much capex was deployed in H1? Is working capital inflating (inventory buildup, receivables stretch) or stabilizing? Capex intensity in H2 will determine FCF and dividend sustainability. If management signals slower H2 spend or better receivables days, that's a green light on cash generation; if not, margin gains may be offset by cash burn concerns.
ELECON reports Oct 14 into a backdrop of full analyst consensus (Buy, ₹600 target) but FII skepticism (ownership down 260 bps YoY). Q1's 30% sequential revenue drop spooked the market; Q2 is the inflection test. Expect the Street to focus on sequential stabilization (₹550–580 Cr) and PAT margin hold/improvement (13–15%), with the real catalyst on management's tone regarding capex payoff and Q3/Q4 pipeline. Order backlog supports growth, but utilization ramp is the lynchpin. A flat-to-modest-growth print with margin confidence resets the narrative toward FY28; any sign of demand weakness or capex strain pushes the ₹600 target under pressure.